SMF Notes 07:53 GSK GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences

(HGSI) for $13/share in cash to 5:00pm EST July 20 (45.00 )

GSK's tender offer will expire after 16 July, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on 19 April after GSK made a private proposal on 11 April. GSK believes the three months that will have passed since the start of this process is more than adequate time for the HGS Board to bring it to completion. Extension of the tender offer to 20 July will provide HGS shareholders the opportunity to evaluate the outcome of the HGS Board's process relative to GSK's offer. Based on circumstances at that time, GSK will consider all available options regarding its offer but can make no assurance that the tender offer will be further extended. As GSK has clearly stated, the co remains willing to meet and review its offer with HGS at any time. GSK's offer, which is not conditioned on due diligence or financing, represents a premium of 81% to HGS's closing share price of US$7.17 on 18 April, the last trading day before HGS publicly disclosed GSK's private offer.